JW Lifescience (234080) Fundamentals 2026 — P/E 5.8x, Revenue Analysis | SniperIQ
JW Lifescience (234080) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩168.2B, trading at ₩10860.00 on the KSC. This SniperIQ fundamentals page covers JW Lifescience's valuation (P/E 5.8x, P/B 0.8x), profitability (net margin 11.9%), revenue (₩257.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is JW Lifescience's market cap?
JW Lifescience (234080) has a market capitalization of approximately ₩168.2B, trading at ₩10860.00 on the KSC. Market cap moves with the live share price.
What is JW Lifescience's P/E ratio?
JW Lifescience's trailing twelve-month P/E ratio is 5.8x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is JW Lifescience?
JW Lifescience runs a net profit margin of 11.9%, a gross margin of 29.2%, and an operating margin of 13.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does JW Lifescience generate?
JW Lifescience reported revenue of ₩257.8B for fiscal year 2025, with net income of ₩28.6B and earnings per share (EPS) of 1847.38. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does JW Lifescience pay a dividend?
JW Lifescience offers a trailing dividend yield of about 5.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is JW Lifescience financially healthy?
JW Lifescience carries a debt-to-equity ratio of 0.19x and a current ratio of 1.09x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is JW Lifescience a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For JW Lifescience (234080) the key facts are: market cap ₩168.2B, P/E 5.8x, revenue ₩257.8B, 52-week range 10600-15580. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track JW Lifescience's full fundamentals live
Get JW Lifescience's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.